Summary:
A Double-blind, Placebo- and Active-controlled Evaluation of the Safety and Efficacy of Levomilnacipran ER in Pediatric Patients 7-17 Years With Major Depressive Disorder or kids and adolescents suffering from depressive symptoms.
Qualified Participants Must:
• Have signs or symptoms of depression or already be diagnosed by a healthcare professional
•
Between the ages of 7-17
•
Willing and able to come in for weekly vistis over a 2-3 month period
•
Willing and able to complete occassional blood draws and EKGs
Qualified Participants May Receive:
-Free study related medication
-Free study related medical office visits
-May qualify for free transportation
-Compensated $75 per office visit